We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Danaher Purchases Life Science Businesses for US $1.1 Billion

By LabMedica International staff writers
Posted on 07 Sep 2009
Danaher Corp. More...
(DHR; Washington, DC, USA) will acquire life science instrumentation businesses from MDS Inc. (Mississauga, ON, Canada) and Life Technologies (Carlsbad, CA, USA). The company has signed a definitive agreement with MDS Inc. to acquire its analytical technologies division, which includes a 50% ownership position in Applied Biosystems (Foster City, CA, USA)/MDS Sciex joint venture (AB Sciex), a mass spectrometry business, and a 100% ownership position in the former Molecular Devices Corporation (Sunnyvale, CA, USA), a bioresearch and analytical instrumentation company.

In a separate but related transaction, Danaher signed a definitive agreement with Life Technologies Corp. to acquire the remaining 50% ownership position in AB Sciex. After completion of both transactions, Danaher will own outright AB Sciex and MDS. The aggregate purchase price for the combined transactions is $1.1 billion, including debt assumed and net of cash acquired.

The transaction with MDS Inc. is subject to approval of the MDS shareholders. Both transactions are subject to regulatory approval and customary closing conditions, including the absence of material adverse change with respect to the acquired businesses. Danaher expects the transactions to close in the fourth quarter of 2009.

The acquired businesses will operate within Danaher's medical technologies segment and will expand the segment's annual revenues by more than $650 million. Danaher's life sciences and diagnostics annual revenues will increase to more than $2 billion.

AB Sciex designs and manufactures mass spectrometers, and instruments used by clinicians and researchers to identify and quantify specific molecules in complex samples. Typical applications include diagnostics testing, drug development, food and environmental safety testing, and proteomics research. MDS supplies bioanalytical instrumentation.

Danaher designs, manufactures, and markets products and services to professional, medical, industrial, and commercial customers. Its portfolio of brands is well recognized in each of its markets.

Related Links:
Danaher Corp.
MDS Inc.
AB Sciex
Life Technologies Corp.
Molecular Devices Corporation



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.